Fusion Antibodies (FAB.L) Stock Price

£6.5 0%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    6

  • Fundamental

    3

  • Technical

    6

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Fusion Antibodies, AI stock picks, stock alerts and much more.

Sign up

FAB.L AI Stock Analysis

AI stock analysis for FAB.L is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Fusion Antibodies (FAB.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Fusion Antibodies (FAB.L) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Fusion Antibodies (FAB.L), currently trading at £6.5, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About FAB.L

LSE

  • Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.

  • Symbol

    FAB.L

  • Market

    LSE

  • Industry

    Biotechnology

  • Market Cap

    7.4M

Similar Stocks

0I0X.L Codexis
0I0X.L		 $2.11
0.4%
3
ONT.L Oxford Nanopore Technologies plc
ONT.L		 £117.9
0.3%
6
SAR.L Sareum Holdings
SAR.L		 £17.5
5.4%
2
0K1R.L Viridian Therapeutics
0K1R.L		 $12.91
0.7%
5
AVCT.L Avacta Group Plc
AVCT.L		 £35
5.4%
3

News

Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis

Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis
April 16, 2025. Financial Post
Viruses of parasites: A roadmap toward diagnostic and therapeutic development

Viruses of parasites: A roadmap toward diagnostic and therapeutic development
April 10, 2025. Plos.org
Allosteric modulation by the fatty acid site in the glycosylated SARS-CoV-2 spike

Allosteric modulation by the fatty acid site in the glycosylated SARS-CoV-2 spike
April 9, 2025. Elifesciences.org
Eton Pharmaceuticals (NASDAQ:ETON) versus Aravive (NASDAQ:ARAV) Financial Analysis

Eton Pharmaceuticals (NASDAQ:ETON) versus Aravive (NASDAQ:ARAV) Financial Analysis
April 3, 2025. ETF Daily News

FAB.L Alternative Data

Web Traffic

Fusion Antibodies receives an estimated 1536 monthly visitors to fusionantibodies.com.

  • Web Traffic

    1536

  • Change from Previous Month

    66.2%

  • 3 Month Change

    7.3%

  • YoY Change

    7.3%

News Mentions

Fusion Antibodies was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    100%

  • 3 Month Change

    0%

Twitter Followers

Fusion Antibodies has 1,214 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.1% over the last month.

  • Twitter Followers

    1214

  • Daily Change

    0%

  • 1 Month Change

    0.1%

  • 3 Month Change

    0.6%

Facebook Engagement

Fusion Antibodies has engaged 0 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

LinkedIn Followers

5,116 are following Fusion Antibodies on LinkedIn, up by 1.5% over the last month.

  • LinkedIn Followers

    5116

  • Daily Change

    0%

  • 1 Month Change

    1.5%

  • 3 Month Change

    3.8%

Job Postings

Fusion Antibodies currenly has an estimated 0 open job postings.

  • Job Postings

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

LinkedIn Employees

According to LinkedIn, Fusion Antibodies has 28 employees.

  • LinkedIn Employees

    28

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Reddit Mentions

Fusion Antibodies has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • 1 Month Change

    0%

Business Outlook

According to employee reviews, the business outlook among employees at Fusion Antibodies is 60 out of 100 (neutral).

  • Business Outlook

    60

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

FAB.L Financials

FAB.L Key Metrics

  • Total Revenue

    £595K

  • Net Income

    -£869K

  • Earnings per Share

    -£0.017

  • Free cash flow

    -£421K

  • EBITDA

    -£778K

  • EBITDA Ratio

    -1.30756

  • Total Assets

    £2.4M

FAB.L 2-year Revenue & Income
FAB.L 2-year Free Cash Flow

FAB.L Technicals

FAB.L SMA
FAB.L RSI

FAQ

What's the current price of Fusion Antibodies (FAB.L) Stock?
The price of an Fusion Antibodies (FAB.L) share is £6.5.

What's the market cap of Fusion Antibodies?
The current market cap of Fusion Antibodies is 7.4M.

Should I buy or sell FAB.L?
Fusion Antibodies shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Fusion Antibodies is better viewed as a hold or accumulate position while waiting for further developments.

Is Fusion Antibodies a good investment?
The current analysis of Fusion Antibodies' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Fusion Antibodies' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Fusion Antibodies (FAB.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Fusion Antibodies stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Fusion Antibodies (FAB.L) that investors often compare it to?
Fusion Antibodies (FAB.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Viridian Therapeutics and Avacta Group Plc.

What is the forecast for Fusion Antibodies' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Fusion Antibodies' stock price to be around £6.57 in 2026. Starting from the current price of £6.5, this represents a 1% change in price, indicating a neutral outlook for the stock.

How to buy Fusion Antibodies (FAB.L) Stock?
Fusion Antibodies stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Fusion Antibodies shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.